TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP), “Nanobac” or “the Company” announces that it intends to participate in the High Risk Plaque (HRP) Initiative to research and advance the understanding, recognition and management of vulnerable plaque, the primary underlying cause of heart attacks. The HRP Initiative is being conducted by BG-Medicine (BGM) together with Merck & Co., AstraZeneca, Royal Philips Electronics and Humana.